Publikationen Zentrum für das Multiple Myelom


Mateos MV, Weisel K, Martin T, Berdeja JG, Jakubowiak A, Stewart AK, Jagannath S, Lin Y, Diels J, Ghilotti F, Thilakarathne P, Perualila NJ, Cabrieto J, Haefliger B, Erler-Yates N, Hague C, Jackson CC, Schecter JM, Strulev V, Nesheiwat T, Pacaud L, Einsele H, Moreau P (2023)
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, IMiD and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
Haematologica 2023 Aug 1; 108(8): 2192-2204

Zur Publikation

Zhou X, Rasche L, Kortüm KM, Mersi J, Einsele H (2023) BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.
Haematologica 2023 Apr 1; 108(4): 958-968

Zur Publikation


Bladé J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, Rasche L, Rosiñol L, Usmani SZ, Zamagni E, Richardson P (2022)
Extramedullary disease in multiple myeloma: a systematic literature review.
Blood Cancer Journal 2022 Mar 21; 12(3): 45
Zur Publikation

Böckle D, Tabares P, Zhou X, Schimanski S, Steinhardt MJ, Bittrich M, Seebacher E, Ulbrich M, Wilnit A, Metz C, Heidemeier A, Bley T, Werner R, Buck A, Einsele H, Kortüm KM, Beilhack A, Rasche L (2022)
Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma.
British Journal of Haematology 2022 Aug; 198(3): 515-522
Zur Publikation

Bögelein A, Stolzenburg A, Eiring P, Lückerath K, Munawar U, Werner R, Schirbel A, Samnick S, Kortüm KM, Sauer M, Lapa C, Buck AK (2022)
CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents.
Leukemia & Lymphoma 2022 Oct; 63(10): 2393-2402

Zur Publikation

Brandl A, Solimando AG, Mokhtari Z, Tabares P, Medler J, Manz H, Da Vià MC, Croci GA, Kurzwart M, Thusek S, Schneider T, Ebert R, Jakob F, Einsele H, Beilhack A (2022)
Junctional adhesion molecule C expression specifies a CD138low/neg multiple myeloma cell population in mice and humans.
Blood Advances 2022 Apr 12; 6(7): 2195-2206
Zur Publikation

Brioli A, Nägler TM, Yomade O, Rüthrich MM, Scholl S, Frietsch JJ, Hilgendorf I, Ernst T, Sayer HG, Hochhaus A, Mügge LO, von Lilienfeld-Toal M (2022)
Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort.
Oncology Research and Treatment 2022 Jun 15; 45(9): 494-503
Zur Publikation

Buck AK, Haug A, Dreher N, Lambertini A, Higuchi T, Lapa C, Weich A, Pomper MG, Wester HJ, Zehndner A, Schirbel A, Samnick S, Hacker M, Pichler V, Hahner S, Fassnacht M, Einsele H, Serfling SE, Werner RA (2022)
Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using 68Ga-Pentixafor PET.
The Journal of Nuclear Medicine 2022 Nov; 63(11): 1687-1692.

Zur Publikation

Buck AK, Serfling SE, Lindner T, Hänscheid H, Schirbel A, Hahner S, Fassnacht M, Einsele H, Werner RA (2022) CXCR4-targeted theranostics in oncology.
European Journal of Nuclear Medicine and Molecular Imaging 2022 Oct; 49(12): 4133-4144

Zur Publikation

Cerchione C, Usmani SZ, Stewart AK, Kaiser M, Rasche L, Kortüm M, Mateos MV, Spencer A, Sonneveld P, Anderson KC (2022)
Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment. Frontiers in Oncology 2022 Feb 8; 12:820768

Zur Publikation

Cohen AD, Parekh S, Santomasso BD, Gállego Pérez-Larraya J, van de Donk NWCJ, Arnulf B, Mateos MV, Lendvai N, Jackson CC, De Braganca KC, Schecter JM, Marquez L, Lee E, Cornax I, Zudaire E, Li C, Olyslager Y, Madduri D, Varsos H, Pacaud L, Akram M, Geng D, Jakubowiak A, Einsele H, Jagannath S (2022)
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.
Blood Cancer Journal 2022 Feb 24; 12(2):32
Zur Publikation

Dahlhoff J, Manz H, Steinfatt T, Delgado-Tascon J, Seebacher E, Schneider T, Wilnit A, Mokhtari Z, Tabares P, Böckle D, Rasche L, Martin Kortüm K, Lutz MB, Einsele H, Brandl A, Beilhack A (2022)
Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression.
Leukemia 2022 Mar; 36(3): 790-800 
Zur Publikation

Davies FE, Pawlyn C, Usmani SZ, San-Miguel JF, Einsele H, Boyle EM, Corre J, Auclair D, Cho HJ, Lonial S, Sonneveld P, Stewart AK, Bergsagel PL, Kaiser MF, Weisel K, Keats JJ, Mikhael JR, Morgan KE, Ghobrial IM, Orlowski RZ, Landgren CO, Gay F, Caers J, Chng WJ, Chari A, Walker BA, Kumar SK, Costa LJ, Anderson KC, Morgan GJ (2022)
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.
Blood Cancer Discovery 2022 Jul 6; 3(4): 273-284
Zur Publikation

Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, Cowan A, Poudyal BS, Costello C, Gay F, Cook G, Quach H, Einsele H, Schriber J, Hou J, Costa L, Aljurf M, Chaudhry M, Beksac M, Prince M, Mohty M, Janakiram M, Callander N, Biran N, Malhotra P, Otero PR, Moreau P, Abonour R, Iftikhar R, Silberman R, Mailankody S, Gregory T, Lin Y, Carpenter P, Hamadani M, Usmani S, Kumar S (2022)
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma.
Transplantation and Cell Therapy 2022 Jun; 28(6): 284-293
Zur Publikation

Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U (2022) Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322
Annales of Oncology 2022 Jan; 33(1): 117

Zur Publikation

Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U (2022) Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117].
Annales of Oncology 2022 Sep; 33(9): 988

Zur Publikation

Fischer J, Knop S, Danhof S, Einsele H, Keller D, Löffler C (2022)
The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study.
BMC Cancer 2022 Oct 3; 22(1): 1032

Zur Publikation

García-Guerrero E, Götz R, Doose S, Sauer M, Rodríguez-Gil A, Nerreter T, Kortüm KM, Pérez-Simón JA, Einsele H, Hudecek M, Danhof S (2022)
Publisher Correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia 2022 Jan; 36(1): 297

Zur Publikation

Garderet L, Al Hariri M, Wasielica-Poslednik J, Munder M, Kormányos K, Pena C, Gozzetti A, Zhou X, Waszczuk-Gajda A, Rosinol L, Mikala G, Krzystanski M, Lisch W, Vesole D, Szentmáry N, Jurczyszyn A (2022)
Monoclonal gammopathy of ocular significance (MGOS) - a short survey of corneal manifestations and treatment outcomes.
Leukemia and Lymphoma 2022 Apr; 63(4): 984-990
Zur Publikation

Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua ÁU, Chen D, Vrhovac R, Gribben JG, Kröger N, Einsele H, Yakoub-Agha I (2022)
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).
Annales of Oncology 2022 Mar; 33(3): 259-275 
Zur Publikation

Heidemeier A, Schloetelburg W, Thurner A, Metz C, Heidemeier H, Rasche L, Martin Kortuem K, Boeckle D, Weiland E, Benkert T, Nickel D, Werner R, Buck AK, Bley TA (2022)
Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by 18F-FDG and 11C-methionine PET/CT.
European Journal of Radiology 2022 Oct; 155: 110493

Zur Publikation

Heidemeier A, Thurner A, Metz C, Pabst T, Heidemeier H, Rasche L, Kortüm KM, Einsele H, Grimm R, Weiland E, Bley TA (2022)
Whole-Body MRI with an Ultrahigh b-Value of 2000 s/mm2 Improves the Specificity of Diffusion-Weighted Imaging in Patients with Plasma Cell Dyscrasias.
Academic Radiology 2022 Jan; 29(1): e1-e8

Zur Publikation

Hudecek M, Einsele H (2022)
Highjacking myeloma's niche with beefed-up CAR-Ts. Blood 2022 Jun 30; 139(26): 3671-3672
Zur Publikation

Kegyes D, Constantinescu C, Vrancken L, Rasche L, Gregoire C, Tigu B, Gulei D, Dima D, Tanase A, Einsele H, Ciurea S, Tomuleasa C, Caers J (2022)
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Journal of Hematology & Oncology 2022 Jun 7; 15(1): 78

Zur Publikation

Kocaata Z, Wilke T, Fischer F, Welte R, Einsele H (2022)
Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis.
PharmacoEconomics – Open 2022 Jul; 6(4): 619-628
Zur Publikation

Kraus S, Klassen P, Kircher M, Dierks A, Habringer S, Gäble A, Kortüm KM, Weinhold N, Ademaj-Kospiri V, Werner RA, Schirbel A, Buck AK, Herhaus P, Wester HJ, Rosenwald A, Weber WA, Einsele H, Keller U, Rasche L, Lapa C (2022)
Reduced splenic uptake on 68Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis.
Theranostics 2022 Aug 8; 12(13): 5986-5994

Zur Publikation

Lonial S, Popat R, Hulin C, Jagannath S, Oriol A, Richardson PG, Facon T, Weisel K, Larsen JT, Minnema MC, Abdallah AO, Badros AZ, Knop S, Stadtmauer EA, Cheng Y, Amatangelo M, Chen M, Nguyen TV, Amin A, Peluso T, van de Donk NWCJ (2022)
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.
The Lancet Haematology 2022 Nov; 9(11): e822-e832
Zur Publikation

Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, Vij R, Lindsey-Hill J, Dytfeld D, Angelucci E, Perrot A, Benjamin R, van de Donk NWCJ, Ocio EM, Scheid C, Gay F, Roeloffzen W, Rodriguez-Otero P, Broijl A, Potamianou A, Sakabedoyan C, Semerjian M, Keim S, Strulev V, Schecter JM, Vogel M, Wapenaar R, Nesheiwat T, San-Miguel J, Sonneveld P, Einsele H, Moreau P (2022)
ocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.
Leukemia 2022 May; 36(5): 1371-1376
Zur Publikation

Ohmoto A, Fuji S, Shultes KC, Savani BN, Einsele H (2022)
Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia.
Bone Marrow Transplantation 2022 Jun; 57(6): 874-880
Zur Publikation

Piechotta V, Skoetz N, Engelhardt M, Einsele H, Goldschmidt H, Scheid C; Guideline group (2022) Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance.
Deutsches Ärzteblatt International 2022 Apr 8; 119(14): 253-260.
Zur Publikation

Rasche L, Schinke C, Maura F, Bauer MA, Ashby C, Deshpande S, Poos AM, Zangari M, Thanendrarajan S, Davies FE, Walker BA, Barlogie B, Landgren O, Morgan GJ, van Rhee F, Weinhold N (2022)
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states.
Nature Communications 2022 Aug 3; 13(1): 4517
Zur Publikation

Reinoso-Segura M, Caballero-Velázquez T, Herrera P, Patriarca F, Fanin R, Bruno B, Einsele H, Nahi H, Granell M, López-Corral L, Reguera JL, García-Cadenas I, Gahrton G, Pérez-Simón JA, European Myeloma Network, the European Society for Blood and Marrow Transplantation, and the Spanish Group of Transplantation (2022)
Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment. 
Transplantation and Cellular Therapy 2022 May; 28(5): 258.e1-258.e8.
Zur Publikation

Rodríguez-Otero P, San Miguel JF. 2022 Feb 7. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors (2022)
Post-CAR-T Cell Therapy (Consolidation and Relapse): Multiple Myeloma.
The EBMT/EHA CAR-T Cell Handbook [Internet], Chapter 34: 173-176
Zur Publikation

Saeed MEM, Boulos JC, Mücklich SB, Leich E, Chatterjee M, Klauck SM, Efferth T (2022)
Disruption of Lipid Raft Microdomains, Regulation of CD38, TP53, and MYC Signaling, and Induction of Apoptosis by Lomitapide in Multiple Myeloma Cells. Cancer Genomics Proteomics 2022 Sep-Oct; 19(5): 540-555.

Zur Publikation

Schinke C, Poos AM, Bauer M, John L, Johnson S, Deshpande S, Carrillo L, Alapat D, Rasche L, Thanendrarajan S, Zangari M, Al Hadidi S, van Rhee F, Davies F, Raab MS, Morgan G, Weinhold N (2022) Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Advances 2022 Nov 22; 6(22): 5873-5883
Zur Publikation

Siegmund D, Wagner J, Wajant H. (2022)
TNF Receptor Associated Factor 2 (TRAF2) Signaling in Cancer.
Cancers (Basel). 2022 Aug 22;14(16):4055.
Zur Publikation

Solimando AG, Da Vià MC, Bolli N, Steinbrunn T. (2022)
The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring "Multiple Myelomas". Cancers (Basel). 2022 Jul 4;14(13):3271.
Zur Publikation

Solimando AG, Krebs M, Bittrich M, Einsele H (2022)
The Urgent Need for Precision Medicine in Cancer and Its Microenvironment: The Paradigmatic Case of Multiple Myeloma.
Journal of Clinical Medicine 2022 Sep 16; 11(18): 5461
Zur Publikation

Steinhardt M, Kortüm M, Einsele H, Rasche L (2022) [Monoclonal gammopathy of (un)known significance]. Deutsche Medizinische Wochenschrift 2022 Jun; 147(11): 675-682
Zur Publikation

Terpos E, Dimopoulos MA, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Pompa A, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Gries KS, Fastenau J, Liu K, He J, Kampfenkel T, Qiu Y, Amin H, Carson R, Sonneveld P (2022)
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
American Journal of Hematology 2022 Apr; 97(4): 481-490.
Zur Publikation

Urbano-Ispizua A, Hudecek M. 2022 Feb 7. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors.
CART Initiatives in Europe. 
he EBMT/EHA CAR-T Cell Handbook [Internet]. Cham (CH) Springer 20222022 Feb 7; Chapter 5: 23-28
Zur Publikation

Wefelnberg MM, Niels T, Holtick U, Jundt F, Scheid C, Baumann FT (2022)
Clinical exercise therapy program with multiple myeloma patients: Impacts on feasibility, adherence and efficacy. Supportive Care in Cancer 2022 Nov; 30(11): 9615-9623

Zur Publikation

Yakoub-Agha I, Einsele H. 2022 Feb 7. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors (2022)
Multiple Myeloma.
The EBMT/EHA CAR-T Cell Handbook [Internet]. Cham (CH): Springer; 2022 Feb 7; Chapter 16: 87-90.
Zur Publikation

Zhou X, Ruckdeschel A, Peter J, Böckle D, Hornburger H, Danhof S, Steinhardt MJ, Heimeshoff L, Einsele H, Kortüm KM, Rasche L (2022)
Salvage therapy with "Dara- KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma.
Hematological Oncology 2022 Apr; 40(2): 202-211

Zur Publikation


Bachmann F, Schreder M, Engelhardt M, Langer C, Wolleschak D, Mügge LO, Dürk H, Schäfer-Eckart K, Blau IW, Gramatzki M, Liebisch P, Grube M, V Metzler I, Bassermann F, Metzner B, Röllig C, Hertenstein B, Khandanpour C, Dechow T, Hebart H, Jung W, Theurich S, Maschmeyer G, Salwender H, Hess G, Bittrich M, Rasche L, Brioli A, Eckardt KU, Straka C, Held S, Einsele H, Knop S (2021)
Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM.
Cancers (Basel) 2021 Mar 16; 13(6): 1322
Zur Publikation

Bazarbachi AH, Labopin M, Kröger N, Brecht A, Blaise D, Clausen J, Fanin R, Einsele H, Cavanna L, Itäla-Remes M, Bulabois CE, Kündgen L, Martin H, Schmid C, Wagner-Drouet EM, Alakel N, Bazarbachi A, Savani B, Nagler A, Mohty M (2021)
Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia.
Clinical Lymphoma, Myeloma Leukemia 2021 Dec 1; 21(12): 831-840
Zur Publikation

Bruno B, Wäsch R, Engelhardt M, Gay F, Giaccone L, D'Agostino M, Rodríguez- Lobato LG, Danhof S, Gagelmann N, Kröger N, Popat R, Van de Donk NWCJ, Terpos E, Dimopoulos MA, Sonneveld P, Einsele H, Boccadoro M (2021)
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.
Haematologica 2021 Aug 1; 106(8): 2054-2065
Zur Publikation

Da Vià MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, Zhou X, Danhof S, Kraus S, Chatterjee M, Meggendorfer M, Twardziok S, Goebeler ME, Topp MS, Hudecek M, Prommersberger S, Hege K, Kaiser S, Fuhr V, Weinhold N, Rosenwald A, Erhard F, Haferlach C, Einsele H, Kortüm KM, Saliba AE, Rasche L (2021)
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.
Naturmedicine 2021 Apr; 27(4): 616-619
Zur Publikation

Danhof S, Rasche L, Mottok A, Steinmüller T, Zhou X, Schreder M, Kilian T, Strifler S, Rosenwald A, Hudecek M, Einsele H, Gerhard-Hartmann E (2021)
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns.
Annals of Hematology 2021 Jun; 100(6): 1537-1546
Zur Publikation

Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U, EHA Guidelines Committee, ESMO Guidelines Committee (2021)
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of Oncology 2021 Mar 1; 32(3): 309-322
Zur Publikation

Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U (2021)
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.
Hemasphere 2021 Feb 3; 5(2): e528
Zur Publikation

Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P, APOLLO Trial Investigators (2021)
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
The Lancet Oncology 2021 Jun; 22(6): 801-812
Zur Publikation

Einsele H, Briones J, Ciceri F, García Cadenas I, Falkenburg F, Bolaños N, Heemskerk HMM, Houot R, Hudecek M, Locatelli F, Morgan K, Morris EC, O'Dwyer M, Sierra JG, van den Brink M, van de Loosdrecht AA (2021)
The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies.
Hemasphere 2021 Sep 10; 5(10): e642
Zur Publikation

Fernández de Larrea C, Kyle R, Rosiñol L, Paiva B, Engelhardt M, Usmani S, Caers J, Gonsalves W, Schjesvold F, Merlini G, Lentzch S, Ocio E, Garderet L, Moreau P, Sonneveld P, Badros A, Gahrton G, Goldschmidt H, Tuchman S, Einsele H, Durie B, Wirk B, Musto P, Hayden P, Kaiser M, Miguel JS, Bladé J, Rajkumar SV, Mateos MV (2021)
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.
Blood Cancer Journal 2021 Dec 2; 11(12): 192
Zur Publikation

García-Guerrero E, Götz R, Doose S, Sauer M, Rodríguez-Gil A, Nerreter T, Kortüm KM, Pérez-Simón JA, Einsele H, Hudecek M, Danhof S (2021)
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.
Leukemia 2021 Jan; 35(1): 201-214
Zur Publikation

Gay F, Günther A, Offidani M, Engelhardt M, Salvini M, Montefusco V, Patriarca F, Aquino S, Pönisch W, Spada S, Schub N, Gentili S, Wäsch R, Corradini P, Straka C, Palumbo A, Einsele H, Boccadoro M, Sonneveld P, Gramatzki M (2021)
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.
Cancer 2021 Sep 15; 127(18): 3413-3421
Zur Publikation 

Geis M, Nowotny B, Bohn MD, Kouhestani D, Einsele H, Bumm T, Stuhler G (2021)
Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments.
Communications Biology 2021 Jan 8; 4(1):44
Zur Publikation

Haertle L, Barrio S, Munawar U, Han S, Zhou X, Vogt C, Fernández RA, Bittrich M, Ruiz-Heredia Y, Da Viá M, Zovko J, Garitano-Trojaola A, Bolli N, Ruckdesche A, Stühmer T, Chatterjee M, Kull M, Krönke J, Agirre X, Martin-Subero JI, Raab P, Einsele H, Rasche L, Martinez-Lopez J, Haaf T, Kortüm KM (2021)
Cereblon enhancer methylation and IMiD resistance in multiple myeloma.
Blood. 2021 Nov 4; 138(18): 1721-1726
Zur Publikation

Hayden PJ, Eikema DJ, de Wreede LC, Koster L, Kröger N, Einsele H, Minnema M, Dominietto A, Potter M, Passweg J, Bermúdez A, Nguyen-Quoc S, Platzbecker U, Tischer J, Ciceri F, Veelken JH, Ljungman P, Schaap N, Forcade E, Carella AM, Gandemer V, Arcese W, Bloor A, Olivieri A, Vincent L, Beksac M, Schönland S, Yakoub-Agha I (2021)
Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party.
Bone Marrow Transplantation 2021 May 11; 56(10): 2367-2381
Zur Publikation

Heine R, Thielen FW, Koopmanschap M, Kersten MJ, Einsele H, Jaeger U, Sonneveld P, Sierra J, Smand C, Uyl-de Groot CA (2021)
Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future.
Hemasphere 2021 Jan 28; 5(2): e524
Zur Publikation

Hose D, Schreder M, Hefner J, Bittrich M, Danhof S, Strifler S, Krauth MT, Schoder R, Gisslinger B, Einsele H, Gisslinger H, Knop S (2021)
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
Journal of Cancer Research and Clinical Oncology 2021 Jan; 147(1): 205-212
Zur Publikation

Leich E, Schreder M, Pischimarov J, Stühmer T, Steinbrunn T, Rudelius M, Brünnert D, Chatterjee M, Langer C, Keppler S, Heredia-Guerrero SC, Einsele H, Knop S, Bargou RC, Rosenwald A (2021)
Novel molecular subgroups within the context of,receptor tyrosine kinase and adhesion signalling in multiple myeloma.
Blood Cancer Journal 2021 Mar 4; 11(3): 51
Zur Publikation 

Ludwig H, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, Zweegman S, Facon T, Driessen C, Hajek R, Dimopoulos MA, Gay F, Avet-Loiseau H, Terpos E, Zojer N, Mohty M, Mateos MV, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, Engelhardt M, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Abildgaard N, Bringhen S, Sonneveld P (2021)
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network.
Leukemia 2021 Jan; 35(1): 31-44
Zur Publikation

Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, Mateos MV, Moreau P, Cavo M, Pawlyn C, Zweegman S, Engelhardt M, Driessen C, Cook G, Dimopoulos MA, Gay F, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Schreder M, Abildgaard N, Hajek R, Zojer N, Kastritis E, Broijl A, Schjesvold F, Boccadoro M, Terpos E (2021)
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network.
The Lancet Haematology 2021 Dec 28; 8(12): e934-e946
Zur Publikation

Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG (2021)
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
The Lancet Oncology 2021 Mar; 22(3): e105-e118
Zur Publikation

Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
The New England Journal of Medicine 2021 Feb 25; 384(8): 705-716
Zur Publikation 

Musto P, Engelhardt M, Caers J, Bolli N, Kaiser M, Van de Donk N, Terpos E, Broijl A, De Larrea CF, Gay F, Goldschmidt H, Hajek R, Vangsted AJ, Zamagni E, Zweegman S, Cavo M, Dimopoulos M, Einsele H, Ludwig H, Barosi G, Boccadoro M, Mateos MV, Sonneveld P, Miguel JS (2021)
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Haematologica 2021 Nov 1; 106(11): 2799-2812
Zur Publikation

Prommersberger S, Reiser M, Beckmann J, Danhof S, Amberger M, Quade-Lyssy P, Einsele H, Hudecek M, Bonig H, Ivics Z (2021)
CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma.
Gene Therapy 2021 Apr 13; 28(9): 560-571
Zur Publikation

Rosiñol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A, Caers J, Cavo M, Dimopoulos MA, Dispenzieri A, Einsele H, Engelhardt M, Fernández de Larrea C, Gahrton G, Gay F, Hájek R, Hungria V, Jurczyszyn A,Kröger N, Kyle RA, Leal da Costa F, Leleu X, Lentzsch S, Mateos MV, Merlini G, Mohty M, Moreau P, Rasche L, Reece D, Sezer O, Sonneveld P, Usmani SZ, Vanderkerken K, Vesole DH, Waage A, Zweegman S, Richardson PG, Bladé J (2021)
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
British Journal of Haematology 2021 Aug; 194(3): 496-507
Zur Publikation

Solimando AG, Da Vià MC, Leone P, Borrelli P, Croci GA, Tabares P, Brandl A, Di Lernia G, Bianchi FP, Tafuri S, Steinbrunn T, Balduini A, Melaccio A, De Summa S, Argentiero A, Rauert-Wunderlich H, Frassanito MA, Ditonno P, Henke E, Klapper W, Ria R, Terragna C, Rasche L, Rosenwald A, Kortüm MK, Cavo M, Ribatti D, Racanelli V, Einsele H, Vacca A, Beilhack A (2021)
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression.
Haematologica 2021 Jul 1; 106(7): 1943-1956
Zur Publikation

Straka C, Salwender H, Knop S, Vogel M, Müller J, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, Bassermann F, Gramatzki M, Rösler W, Wolf HH, Brugger W, Engelhardt M, Fischer T, Liebisch P, Einsele H (2021)
Full or intensity-reduced high- dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma.
European Journal of Haematology 2021 Nov; 107(5): 529-542
Zur Publikation

Truger MS, Duell J, Zhou X, Heimeshoff L, Ruckdeschel A, John M, Riedel A, Hüper S, Peter J, Walter W, Haertle L, Meggendorfer M, Topp MS, Rosenwald A, Da Via MC, Bolli N, Weinhold N, Einsele H, Haferlach C, Kortüm KM, Rasche L (2021)
Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM.
Blood Advances 2021 Oct 12; 5(19): 3794-3798
Zur Publikation 

Zhou X, Bai T, Meckel K, Song J, Jin Y, Kortüm KM, Einsele H, Hou X, Rasche L (2021)
COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan.
Annales of Hematology 2021 Mar; 100(3): 843-846
Zur Publikation

Zhou X, Einsele H, Danhof S (2021)
[CAR T-cell therapy for multiple myeloma].
Der Internist (Berlin) 2021 May 3; 62(6): 605-610
Zur Publikation


Barrio S, Munawar U, Zhu YX, Giesen N, Shi CX, Viá MD, Sanchez R, Bruins L, Demler T, Müller N, Haertle L, Garitano A, Steinbrunn T, Danhof S, Cuenca I, Barrio-Garcia C, Braggio E, Rosenwald A, Martinez-Lopez J, Rasche L, Raab MS, Stewart AK, Einsele H, Stühmer T, Kortüm KM (2020)
IKZF1/3 and CRL4(CRBN) E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma.
Haematologica 2020 May; 105(5): e237-e241
Zur Publikation

Beauvais D, Danhof S, Hayden PJ, Einsele H, Yakoub-Agha I (2020)
Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma.
Current Opinion in Oncology 2020 Sep; 32(5): 418-426
Zur Publikation

Brioli A, Manz K, Pfirrmann M, Hänel M, Schwarzer AC, Prange-Krex G, Fabisch C, Knop S, Illmer T, Krammer-Steiner B, Hochhaus A, von Lilienfeld-Toal M, Mügge LO (2020)
Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).
Journal of Cancer Research and Clinical Oncology 2020 Mar; 146(3): 749-759
Zur Publikation

Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, Hungria V, Engelhardt M, Gay F, García Feria A, Oliva S, Oostvogels R, Gozzetti A, Rosenbaum C, Kumar S, Stadtmauer EA, Einsele H, Beksac M, Weisel K, Anderson KC, Mateos MV, Moreau P, San-Miguel J, Munshi NC, Avet-Loiseau H (2020)
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.
Blood 2020 Dec 24; 136(26): 3033-3040
Zur Publikation

Cordas Dos Santos D, Erickson N, Gerland L, Jundt F, Theurich S (2020)
Primär- und Sekundärprävention des Multiplen Myeloms – Lebensstilfaktoren und Supportivmaßnahmen.
Deutsche Medizinische Wochenschrift 2020 Jun 17; 145(12): 836-842
Zur Publikation

Da Vià MC, Solimando AG, Garitano-Trojaola A, Barrio S, Munawar U, Strifler S, Haertle L, Rhodes N, Teufel E, Vogt C, Lapa C, Beilhack A, Rasche L, Einsele H, Kortüm KM (2020)
CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.
The Oncologist 2020 Feb; 25(2): 112-118
Zur Publikation

Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, Grosicki S, Špička I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Matsumoto M, Wu KL, Anderson KC, Jou YM, Ganetsky A, Singhal AK, Richardson PG (2020)
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.
Blood Cancer Journal 2020 Sep 4; 10(9): 91
Zur Publikation

Einsele H, Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, Kufer P, Iskander K, Kantarjian HM (2020)
The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
Cancer 2020 Jul 15; 126(14): 3192-3201
Zur Publikation

Engelhardt M, Shoumariyeh K, Rösner A, Ihorst G, Biavasco F, Meckel K, von Metzler I, Treurich S, Hebart H, Grube M, Kull M, Bassermann F, Schäfer-Eckart K, Hoferer A, Einsele H, Rasche L, Wäsch R (2020)
Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany.
Haematologica 2020 Dec 1; 105(12): 2872-2878
Zur Publikation

Gran C, Wang J, Nahi H, Koster L, Gahrton G, Einsele H, Niittyvoupio R, Edinger M, Beelen D, Ciceri F, Bornhäuser M, Finke J, de Wreede LC, Ljungman P, Mielke S, Tischer J, Garderet L, Schönland S, Yakoub-Agha I, Kröger N (2020)
Treosulfan conditioning for allogeneic transplantation in multiple myeloma - improved overall survival in first line haematopoietic stem cell transplantation - a large retrospective study by the Chronic Malignancies Working Party of the EBMT.
British Journal of Haematology 2020 Jun; 189(5): e213-e217
Zur Publikation

Heidemeier A, Thurner A, Metz C, Pabst T, Heidemeier H, Rasche L, Kortüm KM, Einsele H, Grimm R, Weiland E, Bley TA (2020)
Whole-Body MRI with an Ultrahigh b-Value of 2000 s/mm(2) Improves the Specificity of Diffusion-Weighted Imaging in Patients with Plasma Cell Dyscrasias.
Academic Radiology 2020 Oct 30: S1076-6332(20)30555-9
Zur Publikation

Jansen L, Merz M, Engelhardt M, Weisel K, Scheid C, Straka C, Langer C, Salwender H, Einsele H, Kröger N, Beelen DW, Dreger P, Goldschmidt H, Brenner H (2020)
Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects. National Registry for Stem Cell Transplants (DRST).
Leukemia & Lymphoma 2020; 61(10): 2365-2374
Zur Publikation

Lejeune M, Köse MC, Duray E, Einsele H, Beguin Y, Caers J (2020)
Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.
Frontiers in Immunology 2020 May 7; 11:762
Zur Publikation

Luber V, Lutz M, Abele-Horn M, Einsele H, Grigoleit GU, Mielke S (2020)
Excretion of Ascaris lumbricoides following reduced-intensity allogeneic hematopoietic stem cell transplantation and consecutive treatment with mebendazole.
Transplant Infectious Disease 2020 Feb 19; 22(1): e13224
Zur Publikation

Ludwig H, Pönisch W, Knop S, Egle A, Hinke A, Schreder M, Lechner D, Hajek R, Gunsilius E, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Rumpold H, Pour L, Jelinek T, Krenosz KJ, Meckl A, Nolte S, Melchardt T, Greil R, Zojer N (2020)
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population.
Leukemia & Lymphoma 2020 Feb; 61(2): 377-386
Zur Publikation 

Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J (2020)
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
The Lancet 2020 Jan 11; 395(10218): 132-141
Zur Publikation

Merz M, Dechow T, Scheytt M, Schmidt C, Hackanson B, Knop S (2020)
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma.
Annals of Hematology 2020 Aug 16; 99(8): 
Zur Publikation

Raab MS, Engelhardt M, Blank A, Goldschmidt H, Agis H, Blau IW, Einsele H, Ferstl B, Schub N, Röllig C, Weisel K, Winderlich M, Griese J, Härtle S, Weirather J, Jarutat T, Peschel C, Chatterjee M (2020)
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
The Lancet Haematology 2020 May; 7(5): e381-e394
Zur Publikation 

Rasche L, Hudecek M, Einsele H (2020)
What is the future of immunotherapy in multiple myeloma?
Blood 2020 Nov 26; 136(22): 2491-2497
Zur Publikation

Rodríguez-Lobato LG, Ganzetti M, Fernández de Larrea C, Hudecek M, Einsele H, Danhof S (2020)
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions.
Frontiers in Oncology 2020 Jul 28; 10: 1243
Zur Publikation

Seibold M, Stühmer T, Kremer N, Mottok A, Scholz CJ, Schlosser A, Leich E, Holzgrabe U, Brünnert D, Barrio S, Kortüm MK, Solimando AG, Chatterjee M, Einsele H, Rosenwald A, Bargou RC, Steinbrunn T (2020)
RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS.
Haematologica 2020 Sep 1; 105(9): 2316-2326
Zur Publikation

Steinhardt MJ, Wiercinska E, Pham M, Grigoleit GU, Mazzoni A, Da-Via M, Zhou X, Meckel K, Nickel K, Duell J, Krummenast FC, Kraus S, Hopkinson C, Weissbrich B, Müllges W, Stoll G, Kortüm KM, Einsele H, Bonig H, Rasche L (2020)
Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes.
Journal of Translational Medicine 2020 Apr 21; 18(1): 177
Zur Publikation

Steinhardt MJ, Zhou X, Krummenast F, Meckel K, Nickel K, Böckle D, Messerschmidt J, Knorz S, Dierks A, Heidemeier A, Lapa C, Einsele H, Rasche L, Kortüm KM (2020)
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma.
International Journal of Immunpathology and Pharmacology 2020 Jan-Dec; 34: 2058738420980258
Zur Publikation

Terpos E, Engelhardt M, Cook G, Gay F, Mateos MV, Ntanasis-Stathopoulos I, van de Donk NWCJ, Avet-Loiseau H, Hajek R, Vangsted AJ, Ludwig H, Zweegman S, Moreau P, Einsele H, Boccadoro M, San Miguel J, Dimopoulos MA, Sonneveld P (2020)
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN).
Leukemia 2020 Aug; 34(8): 2000-2011
Zur Publikation 

Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, Krönke J, Facon T, Salnikov AV, Lesley R, Beutner K, Kalabus J, Rasmussen E, Riemann K, Minella AC, Munzert G, Einsele H (2020)
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.
Journal of Clinical Oncology 2020 Mar 10; 38(8): 775-783
Zur Publikation

Weißbach S, Heredia-Guerrero SC, Barnsteiner S, Großhans L, Bodem J, Starz H, Langer C, Appenzeller S, Knop S, Steinbrunn T, Rost S, Einsele H, Bargou RC, Rosenwald A, Stühmer T, Leich E (2020)
Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines.
Cancers (Basel) 2020 Feb 16; 12(2): 455
Zur Publikation

Weyermann C, Straka C, Einsele H (2020)
[Recurrent Therapy of Multiple Myeloma - Individualized Concepts from The Arsenal of Diverse Options].
Deutsche Medizinische Wochenschrift 2020 Jun; 145(12): 820-827
Zur Publikation 

Zhou X, Dierks A, Kertels O, Kircher M, Schirbel A, Samnick S, Buck AK, Knorz S, Böckle D, Scheller L, Messerschmidt J, Barakat M, Kortüm KM, Rasche L, Einsele H, Lapa C (2020)
18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features.
Cancers (Basel) 2020 Aug 18; 12(8): 2333
Zur Publikation

Zhou X, Dierks A, Kertels O, Samnick S, Kircher M, Buck AK, Haertle L, Knorz S, Böckle D, Scheller L, Messerschmidt J, Barakat M, Truger M, Haferlach C, Einsele H, Rasche L, Kortüm KM, Lapa C (2020)
The Link between Cytogenetics/Genomics and Imaging Patterns of Relapse and Progression in Patients with Relapsed/Refractory Multiple Myeloma: A Pilot Study Utilizing 18F-FDG PET/CT.
Cancers (Basel) 2020 Aug 24; 12(9): 2399
Zur Publikation

Zhou X, Einsele H, Danhof S (2020)
Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma.
Journal of Clinical Medicine 2020 Jul 9; 9(7): 2166
Zur Publikation

Zhou X, Flüchter P, Nickel K, Meckel K, Messerschmidt J, Böckle D, Knorz S, Steinhardt MJ, Krummenast F, Danhof S, Einsele H, Kortüm KM, Rasche L (2020)
Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease.
Cancers (Basel) 2020 Apr 23; 12(4): 1035
Zur Publikation 

Zhou X, Rasche L, Kortüm KM, Danhof S, Hudecek M, Einsele H (2020)
Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies.
Frontiers in Immunology 2020 Dec 23; 11: 620312
Zur Publikation

Zhou X, Steinhardt MJ, Grathwohl D, Meckel K, Nickel K, Leicht HB, Krummenast F, Einsele H, Rasche L, Kortüm KM (2020)
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
Cancer Medicine 2020 Jul 1; 9(16): 5819-5826
Zur Publikation

Ziouti F, Soares AP, Moreno-Jiménez I, Rack A, Bogen B, Cipitria A, Zaslansky P, Jundt F (2020)
An Early Myeloma Bone Disease Model in Skeletally Mature Mice as a Platform for Biomaterial Characterization of the Extracellular Matrix.
Journal of Oncology 2020 Jun 27; 2020: 3985315
Zur Publikation 


Barrio S, Munawar U, Zhu YX, Giesen N, Shi CX, Da Via M, Sanchez R, Bruins L, Demler T, Muller N, Haertle L, Garitano A, Steinbrunn T, Danhof S, Cuenca I, Barrio- Garcia C, Braggio E, Rosenwald A, Martinez-Lopez J, Rasche L, Raab MS, Stewart AK, Einsele H, Stuhmer T, Kortum KM (2019)
IKZF1/3 and CRL4-CRBN E3 ubiquitin ligase mutations and IMiD resistance in multiple myeloma.
Haematologica 2019 
Sep 26; 105(5): e237-e241
Zur Publikation

Barrio S, Stuhmer T, Da-Via M, Barrio-Garcia C, Lehners N, Besse A, Cuenca I, Garitano-Trojaola A, Fink S, Leich E, Chatterjee M, Driessen C, Martinez-Lopez J, Rosenwald A, Beckmann R, Bargou RC, Braggio E, Stewart AK, Raab MS, Einsele H,Kortum KM (2019)
Spectrum and functional validation of PSMB5 mutations in multiple myeloma.
Leukemia 2019 Feb; 33(2): 447-456
Zur Publikation

Bringhen S, Milan A, D'Agostino M, Ferri C, Wasch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, Goldschmidt H, Cavo M, Ludwig H, Driessen C, Auner HW, Caers J, Gramatzki M, Dimopoulos MA, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M (2019)
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.
Journal of Internal Medicine 2019 Jul; 286(1): 63-74
Zur Publikation

Da Via MC, Solimando AG, Garitano-Trojaola A, Barrio S, Munawar U, Strifler S, Haertle L, Rhodes N, Teufel E, Vogt C, Lapa C, Beilhack A, Rasche L, Einsele H, Kortum KM (2019)
CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.
The Oncologist 2019 Oct 18; 25(2): 112-118

Zur Publikation

Danhof S, Strifler S, Hose D, Kortum M, Bittrich M, Hefner J, Einsele H, Knop S, Schreder M (2019)
Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy.
Journal of Cancer Research and Clinical Oncology 2019 Mar; 145(3): 561-571
Zur Publikation

Einsele H, Rasche L, Topp MS, Martin Kortum K, Duell J (2019)
The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT.
Bone Marrow Transplantation 2019 Aug; 54 (Suppl 2): 721-726
Zur Publikation

Greil C, Engelhardt M, Ihorst G, Schoeller K, Bertz H, Marks R, Zeiser R, Duyster J, Einsele H, Finke J, Wasch R (2019)
Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.
Haematologica 2019 Feb; 104(2): 370-379
Zur Publikation

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, Garcia-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S (2019)
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.
The Lancet Oncology 2019 Jun; 20(6): e302-e312
Zur Publikation

Kircher S, Stolzenburg A, Kortum KM, Kircher M, Da Via M, Samnick S, Buck AK, Einsele H, Rosenwald A, Lapa C (2019)
Hexokinase-2 Expression in (11)C-Methionine- Positive, (18)F-FDG-Negative Multiple Myeloma.
The Journal of Nuclear Medicine 2019 Mar; 60(3): 348-352
Zur Publikation

Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, Peest D, Kaufmann M, Bunjes D, Straka C, Fischer T, Sezer O, Hentrich M, Ostermann H, Bassermann F, Hess G, Hertenstein B, Freund M, Kropff M, Schmidt CA, Wolf HH, Jung W, Frickhofen N, Mielke S, Bargou RC, Maschmeyer G, Svaldi M, Langer CH, Gramatzki M, Hebart H, Kanz L, Einsele H (2019)
Deutsche Studiengruppe Multiples M. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis.
Leukemia 2019 Nov; 33(11): 2710-2719
Zur Publikation

Kortum KM, Einsele H (2019)
Diagnostic and therapeutic considerations on recurrence of multiple myeloma : A current overview.
Der Internist (Berl) 2019 Jan; 60(1): 34-41
Zur Publikation

Lapa C, Kircher M, Da Via M, Schreder M, Rasche L, Kortum KM, Einsele H, Buck AK, Hanscheid H, Samnick S (2019)
Comparison of 11C-Choline and 11C-Methionine PET/CT in Multiple Myeloma.
Clinical Nuclear Medicine 2019 Aug; 44(8): 620-624
Zur Publikation

Lapa C, Hanscheid H, Kircher M, Schirbel A, Wunderlich G, Werner RA, Samnick S, Kotzerke J, Einsele H, Buck AK, Wester HJ, Grigoleit GU (2019)
Feasibility of CXCR4- Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma.
Journal of Nuclear Medicine 2019 Jan; 60(1): 60-64
Zur Publikation

Lapa C, Luckerath K, Kircher S, Hanscheid H, Grigoleit GU, Rosenwald A, Stolzenburg A, Kropf S, Einsele H, Wester HJ, Buck AK, Kortum KM, Schirbel A (2019)
Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy.
British Journal of Haematology 2019 Feb; 184(3): 440-443
Zur Publikation

Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S (2019)
Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.
Clinical Lymphoma, Myeloma & Leukrmia 2019 Jan; 19(1): 9-22
Zur Publikation

Loda S, Krebs J, Danhof S, Schreder M, Solimando AG, Strifler S, Rasche L, Kortum M, Kerscher A, Knop S, Puppe F, Einsele H, Bittrich M (2019)
Exploration of Artificial Intelligence Use with ARIES in Multiple Myeloma Research.
Journal of Clinical Medicine 2019 Jul 9; 8(7): 999
Zur Publikation

Ludwig H, Poenisch W, Knop S, Egle A, Schreder M, Lechner D, Hajek R, Gunsilius E, Krenosz KJ, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Melchardt T, Greil R, Zojer N (2019)
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.
British Journal of Cancer 2019 Sept 27; 121(9): 751-757
Zur Publikation

Maurer S, Herhaus P, Lippenmeyer R, Hanscheid H, Kircher M, Schirbel A, Maurer HC, Buck AK, Wester HJ, Einsele H, Grigoleit GU, Keller U, Lapa C (2019)
Side Effects of CXC- Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation.
Journal of Nuclear Medicine 2019 Oct; 60(10): 1399-1405
Zur Publikation

Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Blade J, Delforge M, Hajek R, Ludwig H, Facon T, Miguel JFS, Einsele H (2019)
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.
Haematologica 2019 Dec; 104(12): 2358-2360
Zur Publikation

Munawar U, Rasche L, Muller N, Vogt C, Da-Via M, Haertle L, Arampatzi P, Dietrich S, Roth M, Garitano-Trojaola A, Steinhardt MJ, Strifler S, Gallardo M, Martinez-Lopez J, Bargou RC, Heckel T, Einsele H, Stuhmer T, Kortum KM, Barrio S (2019)
Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness.
Blood 2019 Jul; 134(10): 836-840
Zur Publikation

Nerreter T, Letschert S, Gotz R, Doose S, Danhof S, Einsele H, Sauer M, Hudecek M (2019)
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T.
Nature Communications 2019 Jul; 10(1): 3137
Zur Publikation

Pasca S, Tomuleasa C, Teodorescu P, Ghiaur G, Dima D, Moisoiu V, Berce C, Stefan C, Ciechanover A, Einsele H (2019)
KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma.
Frontiers in  Oncology 2019 Oct 24; 9: 1137
Zur Publikation

Rasche L, Einsele H, Nitschmann S (2019)
Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone.
Der Internist (Berlin) 2019; 60(6): 658-660
No abstract available
Zur Publikation

Solimando AG, Da Via MC, Cicco S, Leone P, Di Lernia G, Giannico D, Desantis V, Frassanito MA, Morizio A, Delgado Tascon J, Melaccio A, Saltarella I, Ranieri G, Ria R, Rasche L, Kortum KM, Beilhack A, Racanelli V, Vacca A, Einsele H (2019)
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment.
Journal of Clinical Medicine 2019 Jul; 8(7): 997
Zur Publikation

Straka C, Knop S, Vogel M, Muller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Durk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rosler W, Wolf HH, Brugger W, Fischer T, Liebisch P, Engelhardt M, Einsele H (2019)
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials.
European Journal of Haematology 2019 Jul 19; 103(3): 255-267
Zur Publikation

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan
G (2019)
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
Leukemia 2019 Jan; 33(1): 159-170
Zur Publikation

Went M, Sud A, Forsti A, Halvarsson BM, Weinhold N, Kimber S, van Duin M, Thorleifsson G, Holroyd A, Johnson DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mitchell JS, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Bandapalli OR, Einsele H, Gregory WA, Gullberg U, Hillengass J, Hoffmann P, Jackson GH, Jockel KH, Johnsson E, Kristinsson SY, Mellqvist UH, Nahi H, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, consortium P, Nickel J, Nothen MM, Rafnar T, Ross FM, da Silva Filho MI, Thomsen H, Turesson I, Vangsted A, Andersen NF, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Goldschmidt H, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Hemminki K, Nilsson B, Houlston RS (2019)
Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.
Nature Communications 2019 Jan 10; 10(1): 213
Zur Publikation

Zilkowski I, Ziouti F, Schulze A, Hauck S, Schmidt S, Mainz L, Sauer M, Albrecht K, Jundt F, Groll J (2019)
Nanogels Enable Efficient miRNA Delivery and Target Gene Downregulation in Transfection-Resistant Multiple Myeloma Cells.
Biomacromolecules 2019 Feb 11; 20(2): 916-926
Zur Publikation

Ziouti F, Ebert R, Rummler M, Krug M, Muller-Deubert S, Ludemann M, Jakob F, Willie BM, Jundt F (2019)
NOTCH Signaling Is Activated through Mechanical Strain in Human Bone Marrow-Derived Mesenchymal Stromal Cells.
Stem Cells International 2019 Feb 26; 2019:5150634
Zur Publikation

Kontakt, Öffnungszeiten, Sprechzeiten


Silke Amelang 
Telefon: +49 931 201-29029
E-Mail: zese@



Montag bis Donnerstag 
von 9.00 bis 11.00 Uhr

von 10.00 bis 12.00 Uhr

Ambulante Sprechstunde

Dienstag, Donnerstag, Freitag
jeweils vormittags nach Vereinbarung


Zentrum für Seltene Erkrankungen | Universitätsklinikum Würzburg |

Ambulanz: Josef-Schneider-Straße 2 | Haus D6 | 97080 Würzburg | Deutschland
Hausadresse: Josef-Schneider-Straße 4 | Haus C14 | 97080 Würzburg | Deutschland
Postadresse: Josef-Schneider-Straße 2 | 97080 Würzburg | Deutschland